Stocks · News reference

UBS Initiates Coverage On Chemed with Buy Rating, Announces Price Target of $650

Sep 25, 2026, 4:00 PMBenzinga Newsdesk

UBS analyst A.J. Rice initiates coverage on Chemed (NYSE:CHE) with a Buy rating and announces Price Target of $650.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 16, 2026, 8:33 PMBenzinga Newsdesk
Chemed’s Subsidiary Roto-Rooter Services Acquires Independent Roto-Rooter Franchise For $60.6M
Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE:CHE) announced it has acquired the largest independent Roto-Rooter franchise, serving a population of approximately
CHE
BenzingaAug 27, 2026, 5:14 PMBenzinga Newsdesk
The Capitol Forum Posts On X "Chemed: Vitas Healthcare Misdiagnosed Dementia Patients and 'Fudged' Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed Internal Documents Says They Warrant Federal Investigation"
https://x.com/Capitol_Forum/status/2093021234103488646
CHE
BenzingaJul 31, 2026, 4:08 PMBenzinga Newsdesk
Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.
CHE